These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19690235)

  • 1. Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in rats.
    Brendt P; Horwat A; Schäfer ST; Dreyer SC; Göthert J; Peters J
    Anesth Analg; 2009 Sep; 109(3):705-11. PubMed ID: 19690235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darbepoetin alpha, a long-acting erythropoeitin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-alpha.
    Brendt P; Frey U; Adamzik M; Schäfer ST; Peters J
    Shock; 2009 Jan; 31(1):50-4. PubMed ID: 18497705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis.
    Onuma S; Honda H; Kobayashi Y; Yamamoto T; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
    Ther Apher Dial; 2015 Dec; 19(6):582-9. PubMed ID: 26481900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model.
    Coccia MA; Cooke K; Stoney G; Pistillo J; Del Castillo J; Duryea D; Tarpley JE; Molineux G
    Exp Hematol; 2001 Oct; 29(10):1201-9. PubMed ID: 11602322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis.
    Brugnara C; Colella GM; Cremins J; Langley RC; Schneider TJ; Rutherford CJ; Goldberg MA
    J Lab Clin Med; 1994 May; 123(5):660-7. PubMed ID: 8195672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.
    Grasso G; Graziano F; Sfacteria A; Carletti F; Meli F; Maugeri R; Passalacqua M; Certo F; Fazio M; Buemi M; Iacopino DG
    Neurosurgery; 2009 Oct; 65(4):763-9; discussion 769-70. PubMed ID: 19834382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats.
    Cassis P; Azzollini N; Solini S; Mister M; Aiello S; Cugini D; Scudeletti P; Gagliardini E; Abbate M; Gallon L; Remuzzi G; Noris M
    Transplantation; 2011 Aug; 92(3):271-9. PubMed ID: 21705971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Smith RE; Aapro MS; Ludwig H; Pintér T; Smakal M; Ciuleanu TE; Chen L; Lillie T; Glaspy JA
    J Clin Oncol; 2008 Mar; 26(7):1040-50. PubMed ID: 18227526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation.
    Pankewycz O; Kulaylat M; Fagan L; Matthews B; Kohli R; Laftavi MR
    Transplant Proc; 2010 Nov; 42(9):3537-41. PubMed ID: 21094811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of darbepoetin-α in spinal cord ischemia-reperfusion injury in the rabbit.
    Yilmaz ER; Kertmen H; Dolgun H; Gürer B; Sanli AM; Kanat MA; Arikok AT; Bahsi SY; Ergüder BI; Sekerci Z
    Acta Neurochir (Wien); 2012 Jun; 154(6):1037-43; discussion 1043-4. PubMed ID: 22354718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity.
    Haiden N; Klebermass K; Cardona F; Schwindt J; Berger A; Kohlhauser-Vollmuth C; Jilma B; Pollak A
    Pediatrics; 2006 Jul; 118(1):180-8. PubMed ID: 16818564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.